Previous close | 0.5000 |
Open | 0.5000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 50.00 |
Expiry date | 2024-08-16 |
Day's range | 0.5000 - 0.5000 |
Contract range | N/A |
Volume | |
Open interest | N/A |
PALO ALTO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on June 6, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 18 new employees in restricted stock units for an aggregate of 90,591 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restri
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that Neil Kumar, Ph.D., founder and CEO of BridgeBio, will present at the Goldman Sachs Annual Global Healthcare Conference in Miami, FL on Wednesday, June 12 at 3:20 pm EDT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” pa
BridgeBio stock gave up gains midday Tuesday after releasing a Phase 2 study on a growth disorder treatment.